Related Experiment Video

Updated: Jul 4, 2026

High-Density Lipoprotein-Specific Phospholipid Efflux Assay
07:08

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

[High and low density lipoprotein abnormalities in coronary patients with LDL-C at target and uncontrolled HDL-C and

Carlos Posadas-Romero1, Rosalinda Posadas-Sánchez, Juan Gabriel Juárez-Rojas

  • 1Departamento de Endocrinologia, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico, DF. cposadasr@yahoo.com

Archivos De Cardiologia De Mexico
|June 28, 2008
PubMed

Insights

Coronary patients on statins with optimal LDL-cholesterol but abnormal HDL-cholesterol and triglycerides have concerning HDL and LDL particle abnormalities. These lipid profile issues indicate a higher risk for future cardiovascular events.

Area of Science:

  • Cardiovascular Medicine
  • Lipid Metabolism
  • Pharmacotherapy

Context:

  • Coronary artery disease (CAD) management often involves statin therapy to lower low-density lipoprotein cholesterol (LDL-C).
  • Despite achieving target LDL-C levels (< 100 mg/dL), some male patients exhibit residual cardiovascular risk due to abnormal high-density lipoprotein cholesterol (HDL-C < 40 mg/dL) and elevated triglycerides (TG ≥ 150 mg/dL).

Purpose:

  • To investigate the characteristics of HDL subclasses, HDL composition, LDL size, and LDL oxidation susceptibility in male CAD patients on statins with optimal LDL-C but abnormal HDL-C and TG levels.
  • To compare these lipid parameters with a control group of statin-treated male CAD patients who have normal HDL-C and TG levels.

Summary:

  • Gradient gel electrophoresis and oxidation assays revealed that patients with low HDL-C and high TG had a lower proportion of large HDL particles and a higher proportion of small HDL particles compared to controls.
  • Furthermore, this patient group exhibited abnormal HDL composition, smaller LDL particle size, and increased LDL susceptibility to oxidation (p < 0.05).

Impact:

  • The study identifies specific lipoprotein abnormalities (HDL subclasses, LDL size, LDL oxidation) in statin-treated coronary patients with suboptimal HDL-C and TG levels.
  • These findings highlight that even with controlled LDL-C, specific lipid subclass dysregulations are associated with increased risk of recurrent coronary events, underscoring the need for comprehensive lipid management.
Abstract

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...